Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-48816274 in healthy participants
NCT02852395Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2016
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-48816274 in Insomnia (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Treatment Emergent Adverse Events, Area Under the Plasma Concentration-Time Curve From Time Zero to Time 't' and 4 more. Started Aug 2016; status: completed.
02
Drugs
JNJ-48816274
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT02852395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02852395.